Pure Global AI
NCT06409390Recruiting

Pilot Study of Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

A Pilot Study of Sequential (First Strike, Second Strike) Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research InstitutePhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Metastatic Breast Cancer
Drug/Device/Intervention
Taxotere
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
H. Lee Moffitt Cancer Center and Research Institute
Location
Tampa, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 01, 2024
End date
Apr 01, 2027
Enrollment
15 participants
Primary outcome

Feasibility of Sequential Therapy

Summary

The purpose of the study is to test a treatment strategy with currently approved drugs to see
 if it is practical to administer the available drugs in a new way that researchers hope could
 be more effective in treating metastatic breast cancer.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastMalignant neoplasm: Overlapping lesion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06409390
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06409390 through Pure Global AI's free database. This Phase 1 trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute and is currently Recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.